BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 28710036)

  • 1. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
    Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
    Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
    Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
    Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
    Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
    J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia.
    Wang SM; Sun LL; Zeng WX; Wu WS; Zhang GL
    Med Oncol; 2014 Jul; 31(7):62. PubMed ID: 24927955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia.
    Li M; Kong XY; Wang SM
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):77-87. PubMed ID: 36463535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K; Bretton-Meyer U
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia.
    Khera S; Trehan A; Bhatia P; Singh M; Bansal D; Varma N
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):341-348. PubMed ID: 30474703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia.
    Buaboonnam J; Sripatanatadasakul P; Treesucon A; Glomglao W; Siraprapapat P; Narkbunnam N; Vathana N; Takpradit C; Phuakpet K; Pongtanakul B; Tongsai S; Sinlapamongkolkul P; Sanpakit K
    Pediatr Int; 2019 Aug; 61(8):754-758. PubMed ID: 31166660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
    He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
    Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia.
    Iparraguirre L; Gutierrez-Camino A; Umerez M; Martin-Guerrero I; Astigarraga I; Navajas A; Sastre A; Garcia de Andoin N; Garcia-Orad A
    Pharmacogenet Genomics; 2016 Nov; 26(11):517-525. PubMed ID: 27649261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):589-595. PubMed ID: 28719513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
    Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
    Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
    Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of variants in folate metabolism genes on 6-mercaptopurine induced toxicity during treatment for childhood acute lymphocytic leukemia.
    Milosevic G; Kotur N; Lazic J; Krstovski N; Stankovic B; Zukic B; Janic D; Jurisic V; Pavlovic S; Dokmanovic L
    J BUON; 2019; 24(5):2075-2083. PubMed ID: 31786878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of ABCB1, ABCC5 and xanthine oxidase genetic polymorphisms with methotrexate adverse reactions in Mexican pediatric patients with ALL.
    Zaruma-Torres F; Lares-Asseff I; Reyes-Espinoza A; Loera-Castañeda V; Chairez-Hernández I; Sosa-Macías M; Galaviz-Hernández C; Almanza-Reyes H
    Drug Metab Pers Ther; 2015 Sep; 30(3):195-201. PubMed ID: 26353179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
    den Hoed MA; Lopez-Lopez E; te Winkel ML; Tissing W; de Rooij JD; Gutierrez-Camino A; Garcia-Orad A; den Boer E; Pieters R; Pluijm SM; de Jonge R; van den Heuvel-Eibrink MM
    Pharmacogenomics J; 2015 Jun; 15(3):248-54. PubMed ID: 25348617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.